Dexcom offers a free trial programme for its G7 and G7 15 Day Continuous Glucose Monitoring (CGM) systems, designed to allow patients and healthcare providers to evaluate the device's suitability for managing diabetes. The programme provides the CGM system at no cost for a limited period, subject to specific eligibility criteria and requirements. The trial is intended for individuals with diabetes who have compatible smart devices and a prescription from a healthcare provider. Dexcom reserves the right to modify or terminate the offer at any time without notice, and the offer is void where prohibited by law.
Eligibility for the free trial is primarily determined by insurance status and medical condition. The programme is available to most individuals aged 18 years and over who have type 1 or type 2 diabetes and are covered by a commercial health insurance plan. Patients on government health plans, including Medicare, Medicaid, and the Veterans Health Administration (VA), are not currently eligible for the free trial. Individuals with prediabetes or those without a diabetes diagnosis are also excluded. For patients under the age of 18, the trial provides the Dexcom G7 system, while those aged 18 and over receive the Dexcom G7 15 Day system.
A valid prescription from a doctor is mandatory to receive a trial device. Patients are required to own a compatible smartphone to use the Dexcom G7 app, which is compatible with most Apple iPhones and Android smartphones. A list of compatible devices is available on the Dexcom website. The programme does not include a compatible smart device, which must be purchased separately.
The process to obtain a trial device involves a request initiated by the patient or their healthcare provider. Once a request is submitted, Dexcom assists in obtaining the necessary prescription on the patient's behalf. After the prescription is secured, the free Dexcom G7 or G7 15 Day system is dispatched directly to the patient's address. The shipping timeframe is typically within one week of receiving the patient's consent and the doctor's prescription. Patients receive a tracking number to monitor the delivery. For assistance, patients can contact the provided support number or use a personalised link sent via email to progress with long-term use of the device. Healthcare providers can also expedite the process by returning the request to ASPN pharmacies directly.
The Dexcom G7 system is a real-time CGM that provides glucose readings without the need for finger pricks. The system consists of a small sensor worn on the arm that measures glucose levels in the interstitial fluid and a transmitter that sends the data to a compatible smartphone app. The app displays current glucose levels, trends, and alerts for high or low glucose concentrations, helping users to manage their diabetes more effectively. The G7 15 Day system offers a longer wear time compared to the standard G7 sensor.
Medicare coverage for Dexcom CGM systems is available for patients who meet specific coverage criteria set by the Centres for Medicare & Medicaid Services (CMS). However, this coverage is separate from the free trial programme, which is not available to Medicare beneficiaries. Commercial insurance coverage varies, but the trial is designed for those with commercial plans.
The provided documentation does not specify the duration of the free trial period, nor does it detail the process for requesting additional sensors to continue use beyond the initial trial. It is also unclear if the trial is available to UK residents or only within the United States, as the contact number and pharmacy references are US-based. The terms and conditions state that the complete version is available on provider.dexcom.com/prescribe-sample or dexcomprovider.com/hello. Patients are advised to consult these official resources for the most current and comprehensive details.